Shattuck Labs Q1 net loss widens as R&D spends rise

Shattuck Labs, Inc.

Shattuck Labs, Inc.

STTK

0.00


Overview

  • US biotechnology firm's Q1 net loss widened yr/yr as operating expenses increased

  • Company reported no revenue for Q1 2026

  • Cash and equivalents rose to $90.4 mln, expected to fund operations into 2029


Outlook

  • Shattuck expects to release Phase 1 SL-325 data in Q2 2026

  • Company expects to initiate Phase 2 SL-325 trial in Crohn's disease in Q3 2026

  • Shattuck expects current cash and equivalents to fund operations into 2029


Result Drivers

  • HIGHER R&D SPENDING - Q1 research and development expenses rose as company advanced clinical and preclinical programs

  • NO REVENUE - Company reported no revenue for Q1 2026 as it remains in clinical-stage development


Company press release: ID:nGNX6JrTg9


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Net Income

-$14.77 mln

Q1 Basic EPS

-$0.13

Q1 Income From Operations

-$15.55 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Shattuck Labs Inc is $14.00, about 109.6% above its May 6 closing price of $6.68


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.